BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 7049375)

  • 1. Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.
    Capizzi RL
    Cancer Treat Rep; 1981; 65 Suppl 4():115-21. PubMed ID: 7049375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA; Morgenstern B; Capizzi RL
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential combination of methotrexate and L-asparaginase in the treatment of refractory acute leukemia.
    Amadori S; Tribalto M; Pacilli L; De Laurentis C; Papa G; Mandelli F
    Cancer Treat Rep; 1980; 64(8-9):939-42. PubMed ID: 6934851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of methotrexate cytotoxicity by asparaginase inhibition of methotrexate polyglutamate formation.
    Jolivet J; Cole DE; Holcenberg JS; Poplack DG
    Cancer Res; 1985 Jan; 45(1):217-20. PubMed ID: 2578094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer.
    Yap HY; Benjamin RS; Blumenschein GR; Hortobagyi GN; Tashima CK; Buzdar AU; Bodey GP
    Cancer Treat Rep; 1979 Jan; 63(1):77-83. PubMed ID: 369695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults.
    Yap BS; McCredie KB; Keating MJ; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1981; 65 Suppl 1():83-7. PubMed ID: 6948610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture.
    Kano Y; Ohnuma T; Okano T; Holland JF
    Cancer Res; 1988 Jan; 48(2):351-6. PubMed ID: 3422052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of methotrexate--with emphasis on use of high doses.
    Bertino JR
    Cancer Treat Rep; 1981; 65 Suppl 1():131-5. PubMed ID: 6976829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
    Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
    Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood.
    Lobel JS; O'Brien RT; McIntosh S; Aspnes GT; Capizzi RL
    Cancer; 1979 Mar; 43(3):1089-94. PubMed ID: 284840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability.
    Keefe DA; Capizzi RL; Rudnick SA
    Cancer Res; 1982 May; 42(5):1641-5. PubMed ID: 7066887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary results of the combination methotrexate-asparaginase in patients with acute non lymphoid leukemia.
    Mandelli F; Amadori S; Pacilli L; Tribalto M
    Biomedicine; 1978 Jun; 29(4):116-7. PubMed ID: 687752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of amino acid depletion in combined treatment of neoplastic cells with methotrexate and L-asparaginase.
    Chlopkiewicz B; Koziorowska J
    Cancer Res; 1975 Jun; 35(6):1524-9. PubMed ID: 805660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells.
    De Soto JA; Bowen D; Davis JH; Southerland WM; Hawkins M
    Anticancer Res; 2002; 22(2A):1007-9. PubMed ID: 12014617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo.
    Bender RA; Nichols AP; Norton L; Simon RM
    Cancer Treat Rep; 1978 Jul; 62(7):997-1003. PubMed ID: 688252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate dose methotrexate and sequential L-asparaginase for treatment of refractory acute lymphocytic leukaemia.
    Shetty PA; Kurkure PA; Dasgupta A
    Indian J Cancer; 1984; 21(1):45-9. PubMed ID: 6595214
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
    Klubes P; Cerna I
    Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group.
    Ertel IJ; Nesbit ME; Hammond D; Weiner J; Sather H
    Cancer Res; 1979 Oct; 39(10):3893-6. PubMed ID: 383278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schedule-dependent therapeutic synergism for L-asparaginase and methotrexate in leukemic (L5178Y) mice.
    Vadlamudi S; Krishna B; Reddy VV; Goldin A
    Cancer Res; 1973 Sep; 33(9):2014-9. PubMed ID: 4725366
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.